FERNANDES, K. C. D.; MOURA, M. B. S.; http://lattes.cnpq.br/2236542862418823; http://lattes.cnpq.br/5116832466288181; FERNANDES, Kyvia Cristiane Duarte.; MOURA, Maria Beatriz de Souza.
Résumé:
Immunobiologicals are emerging as an alternative to some serious
allergic conditions, especially allergic asthma and atopic dermatitis (AD).
Objective: To verify that omalizumab, benralizumab and dupilumab compared to
placebo contribute to clinical improvement in patients with asthma and atopic
dermatitis who do not respond well to conventional treatments. Method: Systematic
review with secondary analysis of placebo-controlled, double-blind, randomized
controlled trial data on immunobiologicals used in the treatment of asthma and
atopic dermatitis, using the descriptors: “omalizumabalergia”,
“benralizumabalergia” e “dupilumabalergia” and their englishcorrespondentes in the
virtual databases: LILACS, MEDLINE, Pubmed and Scielo in portuguese, english e
Spanish. Results: In the selected clinical trials, it was observed that omalizumab,
benralizumab and dupilumab showed good response for asthma and moderate to
severe AD control compared with the placebo group. In addition, we observed a
higher prevalence of adverse events in the placebo group, but found a significant
occurrence of airway disorders and injection site reaction. Conclusion: It was
observed, through the analysis of the selected clinical trials, that moderate to severe
asthma and atopic dermatitis can be well controlled with complementary
immunobiological therapy and with the analysis of adverse effects, safety with
omalizumab, benralizumab and dupilumab is demonstrated.